Randomized prospective comparison of everolimus-eluting vs. Sirolimus-eluting stents in patients undergoing percutaneous coronary intervention ― 3-year clinical outcomes of the EXCELLENT randomized trial

Kyung Woo Park, Tae Min Rhee, Hyun Jae Kang, Bon Kwon Koo, Hyeon Cheol Gwon, Jung Han Yoon, Do Sun Lim, In Ho Chae, Kyoo Rok Han, Taehoon Ahn, Myung Ho Jeong, Dong Woon Jeon, Yang Soo Jang, Hyo Soo Kim

Research output: Contribution to journalArticlepeer-review

1 Citation (Scopus)

Abstract

Background: Everolimus-eluting stents (EES) have equivalent short-term angiographic and clinical outcomes to sirolimus-eluting stents (SES), but EES may be superior to SES with regard to long-term clinical safety. We report the 3-year clinical outcomes of EES and SES from the prospective EXCELLENT Randomized Trial (NCT00698607). Methods and Results: We randomly assigned 1,443 patients undergoing percutaneous coronary intervention 3:1 to receive EES and SES, respectively. We investigated endpoints including target lesion failure (TLF) and individual clinical outcomes including stent thrombosis (ST) at 3 years. For EES and SES, the TLF rate was 4.82% and 4.12% (risk ratio [RR], 1.16, 95% CI: 0.65–2.06, P=0.62), respectively. Results were similar in other efficacy endpoints including target lesion revascularization. For safety endpoints, rate of all-cause death was significantly lower for EES (1.67%) than SES (3.57%; RR, 0.46; 95% CI: 0.23–0.94, P=0.03), while the incidence of cardiac death or myocardial infarction was numerically lower in EES. On 1-year landmark analysis, rates of all-cause death and major adverse cardiovascular events were significantly lower for EES than SES. Definite or probable ST was numerically 3-fold higher for SES (1.37%) compared with EES (0.46%). Conclusions: EES and SES had similar efficacy with regard to 3-year outcomes in the EXCELLENT trial, while delayed safety events all trended to favor EES.

Original languageEnglish
Pages (from-to)1566-1574
Number of pages9
JournalCirculation Journal
Volume82
Issue number6
DOIs
Publication statusPublished - 2018

Bibliographical note

Funding Information:
This study was supported by a grant from the Clinical Research Center for Ischemic Heart Disease, Seoul, Korea (0412-CR02-0704-0001), and a grant from the Innovative Research Institute for Cell Therapy, Seoul National University Hospital (A062260), sponsored by the Ministry of Health, Welfare and Family, Korea.

Funding Information:
The authors also received unrestricted grants from Abbott Vascular Korea and Boston Scientific Korea. The funding source had no role in study design, data collection, monitoring, analysis, interpretation, or writing of the manuscript.

Publisher Copyright:
© 2018, Japanese Circulation Society. All rights reserved.

All Science Journal Classification (ASJC) codes

  • Cardiology and Cardiovascular Medicine

Fingerprint

Dive into the research topics of 'Randomized prospective comparison of everolimus-eluting vs. Sirolimus-eluting stents in patients undergoing percutaneous coronary intervention ― 3-year clinical outcomes of the EXCELLENT randomized trial'. Together they form a unique fingerprint.

Cite this